The rapid growth of keysruda in American market

Source: Ding Xiangyuan said on October 31, 2014 that about three-quarters of patients in the United States who are suitable for treatment with keytruda, the company's recently approved cancer drug, are already using the drug A few weeks after keytruda (pembrolizumab) was accelerated by the FDA, the PD-1 inhibitor has been used to treat about 900 melanoma patients, compared with 1200 melanoma patients in the U.S., according to mosadong About three-quarters of patients in the U.S who are suitable for treatment with keytruda, the company's recently approved cancer drug, are already using the drug, Mr mosadon said A few weeks after keytruda (pembrolizumab) was accelerated by the FDA, the PD-1 inhibitor has been used to treat about 900 melanoma patients, compared with 1200 melanoma patients in the U.S., according to mosadong In early September, FDA approved keytruda to be used in patients with non resectable or metastatic melanoma, as well as patients with malignant melanoma after treatment with Bristol Myers Squibb ipimab and BRAF inhibitors (if the mutation of BRAF V600 is positive), such as Roche verofinib and GlaxoSmithKline dalafini Keytruda was approved earlier than competitors such as Bristol Myers Squibb's opdivo (nivolumab) and Roche's mpdl-3280a, but the launch of the drug is still too late to affect the company's sales performance in the third quarter (sales fell 4% to $10.56 billion in the third quarter), but the drug is very promising for MSD With the wholesale purchase cost of US $125, 000 per month for 900 drug patients, MSD is expected to increase its sales by US $100 million in the next 12 months with the indication of melanoma alone, and with keytruda In the new market and for other indications, the sales volume of this drug will increase In addition, as time goes on, there will be further patients who will get worse after using other drugs and are suitable for this drug treatment The drug has just been approved by FDA as a breakthrough treatment drug for advanced non-small cell lung cancer (NSCLC) patients with the deterioration of disease after chemotherapy with platinum containing drugs In the third quarter, as expected, the company's revenue results were affected by the expiration of key product patents, such as the cancer drug temozolomide and the asthma drug montelukast, as well as the hepatitis C treatment drug PegIntron (pegylated interferon α - 2b), which was severely damaged by patients switching to non interferon based treatment schemes On the positive side, sitagliptin's franchise increased by 5% to US $1.4 billion, and its growth in the US and European markets was offset by its price cuts in Japan, while the anti-inflammatory drugs, infliximab and golimub, together generated US $774 million, an 11% increase After increasing by 5%, the sales of infliximab reached US $604 million, while the sales of golimub reached US $170 million, an increase of 35% compared with the same period of 2013, but a slight drop compared with the second quarter of this year "Last October, we launched a multi-year plan to reform MSD, creating a platform for sustained future growth," said Frazier, CEO of MSD "A year later, we provided solid third quarter results and our reforms are moving steadily forward," he added.